IV thrombolysis for acute ischemic stroke: Is there a paradigm shift on the horizon?
From the Department of Neurology (K.M.B.), Mayo Clinic, Jacksonville, FL; and Department of Neurology (R.F.G.), Johns Hopkins University, Baltimore, MD. barrett.kevin@mayo.edu.
Kevin M
KM
Barrett
From the Department of Neurology (K.M.B.), Mayo Clinic, Jacksonville, FL; and Department of Neurology (R.F.G.), Johns Hopkins University, Baltimore, MD.
Rebecca F
RF
Gottesman
D061605:Administration, Intravenous; D002545:Brain Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D020521:Stroke / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000592:standards*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator